WP
KNTE

Woodline Partners’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Woodline Partners’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,089,594
Closed -$6.81M – 791
2023
Q1 		$6.81M Buy
1,089,594
+902,196
+481% +$5.5M 0.09% 249
2022
Q4 		$1.14M Sell
187,398
-337,271
-64% -$2.75M 0.02% 534
2022
Q3 		$6.27M Buy
524,669
+264,393
+102% +$3.46M 0.09% 258
2022
Q2 		$3.28M Hold
260,276
– – 0.05% 322
2022
Q1 		$2.93M Hold
260,276
– – 0.05% 321
2021
Q4 		$4.61M Hold
260,276
– – 0.07% 292
2021
Q3 		$5.99M Hold
260,276
– – 0.1% 229
2021
Q2 		$6.06M Sell
260,276
-25,853
-9% -$658K 0.11% 200
2021
Q1 		$8.92M Buy
286,129
+9,678
+4% +$337K 0.2% 131
2020
Q4 		$11M Buy
+276,451
New +$11.1M 0.29% 104

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Woodline Partners's KNTE Position: Q2 2023 in Review

Woodline Partners sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2023, closing a stake of 1,089,594 shares — an estimated $6.81M sold.

Woodline Partners first reported a position in KNTE in Q4 2020 and held it in 10 quarters. The position peaked at $11M in Q4 2020. 72 funds tracked by Wall St. Rank hold KNTE as of Q2 2023.

  • Woodline Partners reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Woodline Partners sold 1,089,594 Kinnate Biopharma Inc. Common Stock shares in Q2 2023, an estimated $6.81M.
  • Woodline Partners first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 10 quarters.
  • Woodline Partners's Kinnate Biopharma Inc. Common Stock position peaked at $11M in Q4 2020.
  • 72 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2023.

Based on Woodline Partners's 13F filing for Q2 2023, filed 14 Aug 2023.